NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study

被引：0

作者：

Gregorc, V. ^{[1
]}

Ceresoli, G. L. ^{[2
]}

Zucali, P. A. ^{[2
]}

De Braud, F. G. ^{[3
]}

Bajetta, E. ^{[4
]}

Santoro, A. ^{[2
]}

Vigano, M. G. ^{[1
]}

Cappio, F. Caligaris ^{[1
]}

Lambiase, A. ^{[5
]}

Bordignon, C. ^{[5
]}

机构：

[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy

[2] Ist Clin Humanitas, Dept Oncol, Milan, Italy

[3] Ist Europeo Oncol, Clin Pharmacol & New Drugs Unit, Milan, Italy

[4] IRCCS Fdn, Ist Nazl Tumori, Dept Oncol, Milan, Italy

[5] MolMed, Clin Dev, Milan, Italy

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71724-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：509 / 509

页数：1

共 50 条

[31] SAFETY AND ANTITUMOR ACTIVITY OF NGR-HTNF, A SELECTIVE VASCULAR TARGETING AGENT (VTA), ADMINISTERED AT LOW DOSE IN PRE-TREATED PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS OF A PHASE II TRIAL [J].

Citterio, G. ;

Santoro, A. ;

Pressiani, T. ;

Scalamogna, R. ;

Gregorc, V. ;

Rossoni, G. ;

Donadoni, G. ;

Caligaris-Cappio, F. ;

Lambiase, A. ;

Bordignon, C. .

ANNALS OF ONCOLOGY, 2008, 19 :178-178

[32] Phase II study of amrubicin for previously treated patients with malignant pleural mesothelioma. [J].

Akagi, Kazumasa ;

Ikeda, Takaya ;

Nakatomi, Katsumi ;

Taniguchi, Hirokazu ;

Shimada, Midori ;

Gyotoku, Hiroshi ;

Dotsu, Yosuke ;

Umeyama, Yasuhiro ;

Tomono, Hiromi ;

Kitazaki, Takeshi ;

Fukuda, Masaaki ;

Soda, Hiroshi ;

Senju, Hiroaki ;

Takemoto, Shinnosuke ;

Yamaguchi, Hiroyuki ;

Fukuda, Minoru ;

Mukae, Hiroshi .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[33] Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma [J].

Gregorc, Vanesa ;

Zucali, Paolo A. ;

Santoro, Armando ;

Ceresoli, Giovanni L. ;

Citterio, Giovanni ;

De Pas, Tommaso M. ;

Zilembo, Nicoletta ;

De Vincenzo, Fabio ;

Simonelli, Matteo ;

Rossoni, Gilda ;

Spreafico, Anna ;

Vigano, Maria Grazia ;

Fontana, Floriana ;

De Braud, Filippo G. ;

Bajetta, Emilio ;

Caligaris-Cappio, Federico ;

Bruzzi, Paolo ;

Lambiase, Antonio ;

Bordignon, Claudio .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2604-2611

[34] Long-term survival outcomes of a placebo-controlled phase 3 trial with NGR-hTNF in combination with best investigator choice in relapsed malignant pleural mesothelioma (MPM). [J].

Gregorc, Vanesa ;

Lazzari, Chiara ;

Bulotta, Alessandra ;

Vigano, Maria Grazia ;

Ghio, Domenico ;

Fontana, Floriana ;

Salini, Giulia ;

Lambiase, Antonio .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[35] Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients [J].

Lorusso, D. ;

Scambia, G. ;

Amadio, G. ;

di Legge, A. ;

Pietragalla, A. ;

De Vincenzo, R. ;

Masciullo, V. ;

Di Stefano, M. ;

Mangili, G. ;

Citterio, G. ;

Mantori, M. ;

Lambiase, A. ;

Bordignon, C. .

BRITISH JOURNAL OF CANCER, 2012, 107 (01) :37-42

[36] Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours [J].

Gregorc, V. ;

Santoro, A. ;

Bennicelli, E. ;

Punt, C. J. A. ;

Citterio, G. ;

Timmer-Bonte, J. N. H. ;

Cappio, F. Caligaris ;

Lambiase, A. ;

Bordignon, C. ;

van Herpen, C. M. L. .

BRITISH JOURNAL OF CANCER, 2009, 101 (02) :219-224

[37] Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients [J].

D Lorusso ;

G Scambia ;

G Amadio ;

A di Legge ;

A Pietragalla ;

R De Vincenzo ;

V Masciullo ;

M Di Stefano ;

G Mangili ;

G Citterio ;

M Mantori ;

A Lambiase ;

C Bordignon .

British Journal of Cancer, 2012, 107 :37-42

[38] Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM). [J].

Venkatraman, Deepti ;

Anderson, Adrienne ;

Digumarthy, Subba ;

Lizotte, Patrick H. ;

Awad, Mark M. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[39] LACK OF RESPONSE TO CHEMOTHERAPY FOR PREVIOUSLY TREATED MALIGNANT PLEURAL MESOTHELIOMA (MPM) [J].

Zauderer, Marjorie G. ;

Kass, Samantha L. ;

Sima, Camelia S. ;

Ginsberg, Michelle S. ;

Krug, Lee M. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S638-S639

[40] A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM) [J].

Lee, C. W. ;

Anderson, H. ;

Martins, H. ;

Rao, S. C. ;

Sauciuc, D. ;

Laurie, S. A. ;

Morzycki, W. ;

MacNeil, M. V. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →